Johnson & Johnson reported a first-quarter profit that exceeded Wall Street expectations, driven by robust sales of its cancer treatments, particularly its leading blood cancer drug, Darzalex. The company also updated its profit forecasts 2024, reflecting confidence in its portfolio's growth.
